Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:FOLD
CUSIP03152W10
Phone609-662-2000
Debt
Debt-to-Equity Ratio0.32
Current Ratio4.21
Quick Ratio4.15
Price-To-Earnings
Trailing P/E Ratio-5.41
Forward P/E Ratio-12.55
P/E GrowthN/A
Sales & Book Value
Annual Sales$36.93 million
Price / Sales80.69
Cash FlowN/A
Price / CashN/A
Book Value$2.12 per share
Price / Book7.46
Profitability
EPS (Most Recent Fiscal Year)($2.92)
Net Income$-284,000,000.00
Net Margins-563.98%
Return on Equity-60.09%
Return on Assets-29.90%
Miscellaneous
Employees325
Outstanding Shares188,470,000
Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions
What is Amicus Therapeutics' stock symbol?
Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."
How were Amicus Therapeutics' earnings last quarter?
Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.36) by $0.08. The biopharmaceutical company had revenue of $16.70 million for the quarter, compared to analyst estimates of $16.78 million. Amicus Therapeutics had a negative net margin of 563.98% and a negative return on equity of 60.09%. View Amicus Therapeutics' Earnings History.
When is Amicus Therapeutics' next earnings date?
What price target have analysts set for FOLD?
7 brokers have issued 1-year target prices for Amicus Therapeutics' shares. Their predictions range from $15.00 to $24.00. On average, they anticipate Amicus Therapeutics' share price to reach $19.50 in the next year. View Analyst Ratings for Amicus Therapeutics.
Are investors shorting Amicus Therapeutics?
Amicus Therapeutics saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 28,434,123 shares, an increase of 3.1% from the May 15th total of 29,349,145 shares. Based on an average trading volume of 3,293,480 shares, the short-interest ratio is presently 8.6 days. Currently, 15.5% of the shares of the stock are sold short. View Amicus Therapeutics' Current Options Chain.
Who are some of Amicus Therapeutics' key competitors?
Some companies that are related to Amicus Therapeutics include Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), BeiGene (BGNE), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Loxo Oncology (LOXO) and FibroGen (FGEN).
Who are Amicus Therapeutics' key executives?
Amicus Therapeutics' management team includes the folowing people:
- Mr. John F. Crowley, Chairman & CEO (Age 51)
- Mr. Bradley L. Campbell, Pres & COO (Age 42)
- Mr. William D. Baird III, Chief Financial Officer (Age 46)
- Ms. Ellen S. Rosenberg, Gen. Counsel & Corp. Sec. (Age 55)
- Dr. Jay A. Barth, Chief Medical Officer (Age 54)
Has Amicus Therapeutics been receiving favorable news coverage?
Headlines about FOLD stock have been trending somewhat positive on Saturday, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Amicus Therapeutics earned a news sentiment score of 0.02 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 47.61 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Amicus Therapeutics' major shareholders?
Amicus Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.03%), Redmile Group LLC (5.70%), Palo Alto Investors LP (3.26%), Franklin Resources Inc. (2.00%), Farallon Capital Management LLC (1.85%) and Victory Capital Management Inc. (1.63%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.
Which institutional investors are selling Amicus Therapeutics stock?
FOLD stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Highland Capital Management LP, Royal Bank of Canada, Prudential Financial Inc., Copernicus Capital Management LLC, Candriam Luxembourg S.C.A., Seven Eight Capital LP and Russell Investments Group Ltd.. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Margaret G Mcglynn, Michael Raab and William D Baird III. View Insider Buying and Selling for Amicus Therapeutics.
Which institutional investors are buying Amicus Therapeutics stock?
FOLD stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, BlackRock Inc., Sphera Funds Management LTD., Redmile Group LLC, Farallon Capital Management LLC, Victory Capital Management Inc., Loomis Sayles & Co. L P and Delek Group Ltd.. Company insiders that have bought Amicus Therapeutics stock in the last two years include John F Crowley, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.
How do I buy shares of Amicus Therapeutics?
Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amicus Therapeutics' stock price today?
One share of FOLD stock can currently be purchased for approximately $15.81.
How big of a company is Amicus Therapeutics?
Amicus Therapeutics has a market capitalization of $3.11 billion and generates $36.93 million in revenue each year. The biopharmaceutical company earns $-284,000,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Amicus Therapeutics employs 325 workers across the globe.
How can I contact Amicus Therapeutics?
Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]
MarketBeat Community Rating for Amicus Therapeutics (FOLD)
MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe FOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.
